Skip to content

Gilead Sciences

NASDAQ: GILD · USD

Gilead Sciences financials

6 charts

Revenue

USD millions

$7,803M
Gilead Sciences Revenue. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodRevenue
FY 2009 Q2$1,647.155M; Change unavailable vs FY 2009 Q1
FY 2009 Q3$1,801.389M; +9.4% vs FY 2009 Q2
FY 2009 Q4$2,032.379M; +12.8% vs FY 2009 Q3
FY 2010 Q1$2,085.853M; +2.6% vs FY 2009 Q4
FY 2010 Q2$1,927.224M; −7.6% vs FY 2010 Q1
FY 2010 Q3$1,937.656M; +0.5% vs FY 2010 Q2
FY 2010 Q4$1,998.687M; +3.1% vs FY 2010 Q3
FY 2011 Q1$1,926.094M; −3.6% vs FY 2010 Q4
FY 2011 Q2$2,137.253M; +11.0% vs FY 2011 Q1
FY 2011 Q3$2,121.66M; −0.7% vs FY 2011 Q2
FY 2011 Q4$2,200.378M; +3.7% vs FY 2011 Q3
FY 2012 Q1$2,282.449M; +3.7% vs FY 2011 Q4
FY 2012 Q2$2,405.186M; +5.4% vs FY 2012 Q1
FY 2012 Q3$2,426.597M; +0.9% vs FY 2012 Q2
FY 2012 Q4$2,588.285M; +6.7% vs FY 2012 Q3
FY 2013 Q1$2,531.635M; −2.2% vs FY 2012 Q4
FY 2013 Q2$2,767.394M; +9.3% vs FY 2013 Q1
FY 2013 Q3$2,782.833M; +0.6% vs FY 2013 Q2
FY 2013 Q4$3,119.826M; +12.1% vs FY 2013 Q3
FY 2014 Q1$4,998.956M; +60.2% vs FY 2013 Q4
FY 2014 Q2$6,534.943M; +30.7% vs FY 2014 Q1
FY 2014 Q3$6,041.832M; −7.5% vs FY 2014 Q2
FY 2014 Q4$7,314M; +21.1% vs FY 2014 Q3
FY 2015 Q1$7,594M; +3.8% vs FY 2014 Q4
FY 2015 Q2$8,244M; +8.6% vs FY 2015 Q1
FY 2015 Q3$8,295M; +0.6% vs FY 2015 Q2
FY 2015 Q4$8,506M; +2.5% vs FY 2015 Q3
FY 2016 Q1$7,794M; −8.4% vs FY 2015 Q4
FY 2016 Q2$7,776M; −0.2% vs FY 2016 Q1
FY 2016 Q3$7,500M; −3.5% vs FY 2016 Q2
FY 2016 Q4$7,320M; −2.4% vs FY 2016 Q3
FY 2017 Q1$6,505M; −11.1% vs FY 2016 Q4
FY 2017 Q2$7,141M; +9.8% vs FY 2017 Q1
FY 2017 Q3$6,512M; −8.8% vs FY 2017 Q2
FY 2017 Q4$5,949M; −8.6% vs FY 2017 Q3
FY 2018 Q1$5,088M; −14.5% vs FY 2017 Q4
FY 2018 Q2$5,648M; +11.0% vs FY 2018 Q1
FY 2018 Q3$5,596M; −0.9% vs FY 2018 Q2
FY 2018 Q4$5,795M; +3.6% vs FY 2018 Q3
FY 2019 Q1$5,281M; −8.9% vs FY 2018 Q4
FY 2019 Q2$5,685M; +7.7% vs FY 2019 Q1
FY 2019 Q3$5,604M; −1.4% vs FY 2019 Q2
FY 2019 Q4$5,879M; +4.9% vs FY 2019 Q3
FY 2020 Q1$5,548M; −5.6% vs FY 2019 Q4
FY 2020 Q2$5,143M; −7.3% vs FY 2020 Q1
FY 2020 Q3$6,577M; +27.9% vs FY 2020 Q2
FY 2020 Q4$7,421M; +12.8% vs FY 2020 Q3
FY 2021 Q1$6,423M; −13.4% vs FY 2020 Q4
FY 2021 Q2$6,217M; −3.2% vs FY 2021 Q1
FY 2021 Q3$7,421M; +19.4% vs FY 2021 Q2
FY 2021 Q4$7,244M; −2.4% vs FY 2021 Q3
FY 2022 Q1$6,590M; −9.0% vs FY 2021 Q4
FY 2022 Q2$6,260M; −5.0% vs FY 2022 Q1
FY 2022 Q3$7,042M; +12.5% vs FY 2022 Q2
FY 2022 Q4$7,389M; +4.9% vs FY 2022 Q3
FY 2023 Q1$6,352M; −14.0% vs FY 2022 Q4
FY 2023 Q2$6,599M; +3.9% vs FY 2023 Q1
FY 2023 Q3$7,051M; +6.8% vs FY 2023 Q2
FY 2023 Q4$7,114M; +0.9% vs FY 2023 Q3
FY 2024 Q1$6,686M; −6.0% vs FY 2023 Q4
FY 2024 Q2$6,954M; +4.0% vs FY 2024 Q1
FY 2024 Q3$7,545M; +8.5% vs FY 2024 Q2
FY 2024 Q4$7,569M; +0.3% vs FY 2024 Q3
FY 2025 Q1$6,667M; −11.9% vs FY 2024 Q4
FY 2025 Q2$7,082M; +6.2% vs FY 2025 Q1
FY 2025 Q3$7,769M; +9.7% vs FY 2025 Q2
FY 2025 Q4$7,925M; +2.0% vs FY 2025 Q3
FY 2026 Q1$6,960M; −12.2% vs FY 2025 Q4
FY 2026 Q2$7,803M; +12.1% vs FY 2026 Q1
Jun 30, 2009 through Sep 25, 2026

Free cash flow

USD millions

$3,433M
Gilead Sciences Free cash flow. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodFree cash flow
FY 2009 Q2$602.043M; Change unavailable vs FY 2009 Q1
FY 2009 Q3$842.406M; +39.9% vs FY 2009 Q2
FY 2009 Q4$928.289M; +10.2% vs FY 2009 Q3
FY 2010 Q1$658.903M; −29.0% vs FY 2009 Q4
FY 2010 Q2$683.028M; +3.7% vs FY 2010 Q1
FY 2010 Q3$728.616M; +6.7% vs FY 2010 Q2
FY 2010 Q4$701.482M; −3.7% vs FY 2010 Q3
FY 2011 Q1$805.672M; +14.9% vs FY 2010 Q4
FY 2011 Q2$916.62M; +13.8% vs FY 2011 Q1
FY 2011 Q3$832.817M; −9.1% vs FY 2011 Q2
FY 2011 Q4$951.997M; +14.3% vs FY 2011 Q3
FY 2012 Q1$429.77M; −54.9% vs FY 2011 Q4
FY 2012 Q2$1,253.259M; +191.6% vs FY 2012 Q1
FY 2012 Q3$678.784M; −45.8% vs FY 2012 Q2
FY 2012 Q4$435.857M; −35.8% vs FY 2012 Q3
FY 2013 Q1$633.247M; +45.3% vs FY 2012 Q4
FY 2013 Q2$907.728M; +43.3% vs FY 2013 Q1
FY 2013 Q3$715.916M; −21.1% vs FY 2013 Q2
FY 2013 Q4$657.315M; −8.2% vs FY 2013 Q3
FY 2014 Q1$1,404.528M; +113.7% vs FY 2013 Q4
FY 2014 Q2$4,094.296M; +191.5% vs FY 2014 Q1
FY 2014 Q3$3,908.96M; −4.5% vs FY 2014 Q2
FY 2014 Q4$2,853.216M; −27.0% vs FY 2014 Q3
FY 2015 Q1$5,577M; +95.5% vs FY 2014 Q4
FY 2015 Q2$5,487M; −1.6% vs FY 2015 Q1
FY 2015 Q3$3,810M; −30.6% vs FY 2015 Q2
FY 2015 Q4$4,708M; +23.6% vs FY 2015 Q3
FY 2016 Q1$3,736M; −20.6% vs FY 2015 Q4
FY 2016 Q2$4,736M; +26.8% vs FY 2016 Q1
FY 2016 Q3$4,132M; −12.8% vs FY 2016 Q2
FY 2016 Q4$3,317M; −19.7% vs FY 2016 Q3
FY 2017 Q1$2,807M; −15.4% vs FY 2016 Q4
FY 2017 Q2$3,403M; +21.2% vs FY 2017 Q1
FY 2017 Q3$2,565M; −24.6% vs FY 2017 Q2
FY 2017 Q4Unavailable; Change unavailable vs FY 2017 Q3
FY 2018 Q1$2,058M; Change unavailable vs FY 2017 Q4
FY 2018 Q2$1,276M; −38.0% vs FY 2018 Q1
FY 2018 Q3$2,045M; +60.3% vs FY 2018 Q2
FY 2018 Q4$2,097M; +2.5% vs FY 2018 Q3
FY 2019 Q1$1,207M; −42.4% vs FY 2018 Q4
FY 2019 Q2$2,036M; +68.7% vs FY 2019 Q1
FY 2019 Q3$2,699M; +32.6% vs FY 2019 Q2
FY 2019 Q4$2,377M; −11.9% vs FY 2019 Q3
FY 2020 Q1$1,265M; −46.8% vs FY 2019 Q4
FY 2020 Q2$2,423M; +91.5% vs FY 2020 Q1
FY 2020 Q3$2,095M; −13.5% vs FY 2020 Q2
FY 2020 Q4$1,735M; −17.2% vs FY 2020 Q3
FY 2021 Q1$2,445M; +40.9% vs FY 2020 Q4
FY 2021 Q2$2,197M; −10.1% vs FY 2021 Q1
FY 2021 Q3$3,114M; +41.7% vs FY 2021 Q2
FY 2021 Q4$3,049M; −2.1% vs FY 2021 Q3
FY 2022 Q1$1,593M; −47.8% vs FY 2021 Q4
FY 2022 Q2$1,659M; +4.1% vs FY 2022 Q1
FY 2022 Q3$2,706M; +63.1% vs FY 2022 Q2
FY 2022 Q4$2,386M; −11.8% vs FY 2022 Q3
FY 2023 Q1$1,635M; −31.5% vs FY 2022 Q4
FY 2023 Q2$2,199M; +34.5% vs FY 2023 Q1
FY 2023 Q3$1,633M; −25.7% vs FY 2023 Q2
FY 2023 Q4$1,954M; +19.7% vs FY 2023 Q3
FY 2024 Q1$2,114M; +8.2% vs FY 2023 Q4
FY 2024 Q2$1,195M; −43.5% vs FY 2024 Q1
FY 2024 Q3$4,168M; +248.8% vs FY 2024 Q2
FY 2024 Q4$2,828M; −32.1% vs FY 2024 Q3
FY 2025 Q1$1,653M; −41.5% vs FY 2024 Q4
FY 2025 Q2$720M; −56.4% vs FY 2025 Q1
FY 2025 Q3$3,961M; +450.1% vs FY 2025 Q2
FY 2025 Q4$3,122M; −21.2% vs FY 2025 Q3
FY 2026 Q1$2,427M; −22.3% vs FY 2025 Q4
FY 2026 Q2$3,433M; +41.5% vs FY 2026 Q1

Net margin

%

-134.51%
Gilead Sciences Net margin. Reported fiscal history.
Fiscal period%
FY 2009 Q234.69%
FY 2009 Q337.36%
FY 2009 Q439.47%
FY 2010 Q140.99%
FY 2010 Q236.95%
FY 2010 Q336.38%
FY 2010 Q431.49%
FY 2011 Q133.81%
FY 2011 Q234.92%
FY 2011 Q334.93%
FY 2011 Q430.23%
FY 2012 Q119.17%
FY 2012 Q229.36%
FY 2012 Q327.84%
FY 2012 Q429.46%
FY 2013 Q128.53%
FY 2013 Q227.92%
FY 2013 Q328.34%
FY 2013 Q425.37%
FY 2014 Q144.56%
FY 2014 Q255.94%
FY 2014 Q345.21%
FY 2014 Q447.68%
FY 2015 Q157.06%
FY 2015 Q254.49%
FY 2015 Q355.46%
FY 2015 Q455.06%
FY 2016 Q145.75%
FY 2016 Q244.97%
FY 2016 Q344.4%
FY 2016 Q442.46%
FY 2017 Q141.54%
FY 2017 Q243.03%
FY 2017 Q341.74%
FY 2017 Q4-64.97%
FY 2018 Q130.23%
FY 2018 Q232.17%
FY 2018 Q337.47%
FY 2018 Q40.05%
FY 2019 Q137.4%
FY 2019 Q233.07%
FY 2019 Q3-20.79%
FY 2019 Q445.86%
FY 2020 Q127.96%
FY 2020 Q2-64.92%
FY 2020 Q35.47%
FY 2020 Q420.9%
FY 2021 Q126.92%
FY 2021 Q224.48%
FY 2021 Q334.93%
FY 2021 Q45.27%
FY 2022 Q10.29%
FY 2022 Q218.27%
FY 2022 Q325.4%
FY 2022 Q422.2%
FY 2023 Q115.9%
FY 2023 Q215.84%
FY 2023 Q330.92%
FY 2023 Q420.09%
FY 2024 Q1-62.37%
FY 2024 Q223.21%
FY 2024 Q316.61%
FY 2024 Q423.56%
FY 2025 Q119.72%
FY 2025 Q227.68%
FY 2025 Q339.28%
FY 2025 Q427.55%
FY 2026 Q129.04%
FY 2026 Q2-134.51%

P/E

× · TTM · Daily

—
Gilead Sciences P/E. Monthly closing observations; inspect daily values with the chart arrow keys.
Close date× · TTM · DailyFinancials through
2012-02-2912.55×2010-09-30
2012-03-3013.47×2010-09-30
2012-04-3014.34×2010-09-30
2012-05-3113.77×2010-09-30
2012-06-2914.13×2010-09-30
2012-07-3114.97×2010-09-30
2012-08-3115.9×2010-09-30
2012-09-2818.28×2010-09-30
2012-10-3118.52×2010-09-30
2012-11-3020.67×2010-09-30
2012-12-3120.24×2010-09-30
2013-01-3121.75×2010-09-30
2013-02-2826.82×2012-12-31
2013-03-2830.72×2012-12-31
2013-04-3031.79×2012-12-31
2013-05-3131.65×2013-03-31
2013-06-2829.78×2013-03-31
2013-07-3135.67×2013-03-31
2013-08-3034.82×2013-06-30
2013-09-3036.33×2013-06-30
2013-10-3141.13×2013-06-30
2013-11-2941.55×2013-09-30
2013-12-3141.72×2013-09-30
2014-01-3144.8×2013-09-30
2014-02-2845.99×2013-09-30
2014-03-3139.36×2013-09-30
2014-04-3043.6×2013-09-30
2014-05-3045.11×2013-09-30
2014-06-3046.05×2013-09-30
2014-07-3150.85×2013-09-30
2014-08-2959.75×2013-09-30
2014-09-3059.13×2013-09-30
2014-10-3162.21×2013-09-30
2014-11-2855.72×2013-09-30
2014-12-3152.36×2013-09-30
2015-01-3058.23×2013-09-30
2015-02-2757.51×2013-09-30
2015-03-3154.51×2013-09-30
2015-04-3055.83×2013-09-30
2015-05-2962.36×2013-09-30
2015-06-3065.03×2013-09-30
2015-07-3165.47×2013-09-30
2015-08-3158.36×2013-09-30
2015-09-3054.54×2013-09-30
2015-10-3060.06×2013-09-30
2015-11-3058.86×2013-09-30
2015-12-3156.21×2013-09-30
2016-01-2946.1×2013-09-30
2016-02-297.09×2015-12-31
2016-03-317.46×2015-12-31
2016-04-297.16×2015-12-31
2016-05-317.07×2015-12-31
2016-06-306.77×2015-12-31
2016-07-296.45×2015-12-31
2016-08-316.37×2015-12-31
2016-09-306.43×2015-12-31
2016-10-315.98×2015-12-31
2016-11-305.99×2015-12-31
2016-12-305.82×2015-12-31
2017-01-315.88×2015-12-31
2017-02-286.92×2016-12-31
2017-03-316.67×2016-12-31
2017-04-286.73×2016-12-31
2017-05-316.37×2016-12-31
2017-06-306.95×2016-12-31
2017-07-317.47×2016-12-31
2017-08-318.22×2016-12-31
2017-09-297.95×2016-12-31
2017-10-317.36×2016-12-31
2017-11-308.5×2017-09-30
2017-12-298.15×2017-09-30
2018-01-319.53×2017-09-30
2018-02-2822.44×2017-12-31
2018-03-2921.49×2017-12-31
2018-04-3020.59×2017-12-31
2018-05-3119.21×2017-12-31
2018-06-2920.19×2017-12-31
2018-07-3122.18×2017-12-31
2018-08-3121.58×2017-12-31
2018-09-2822.01×2017-12-31
2018-10-3119.43×2017-12-31
2018-11-3020.5×2017-12-31
2018-12-3117.83×2017-12-31
2019-01-3119.95×2017-12-31
2019-02-2818.53×2017-12-31
2019-03-2918.53×2017-12-31
2019-04-3018.54×2017-12-31
2019-05-3123.72×2018-03-31
2019-06-2825.74×2018-03-31
2019-07-3124.97×2018-03-31
2019-08-3037.64×2018-06-30
2019-09-3037.55×2018-06-30
2019-10-3137.74×2018-06-30
2019-11-2955.38×2018-09-30
2019-12-3153.52×2018-09-30
2020-01-3152.05×2018-09-30
2020-02-2857.12×2018-09-30
2020-03-3161.57×2018-09-30
2020-04-3069.18×2018-09-30
2020-05-2964.1×2018-09-30
2020-06-3063.37×2018-09-30
2020-07-3157.26×2018-09-30
2020-08-3154.97×2018-09-30
2020-09-3052.04×2018-09-30
2020-10-3047.89×2018-09-30
2020-11-3049.97×2018-09-30
2020-12-3147.98×2018-09-30
2021-01-2954.03×2018-09-30
2021-02-2628.89×2019-09-30
2021-03-3130.41×2019-09-30
2021-04-3029.86×2019-09-30
2021-05-2831.1×2019-09-30
2021-06-3032.4×2019-09-30
2021-07-3032.13×2019-09-30
2021-08-3134.24×2019-09-30
2021-09-3032.86×2019-09-30
2021-10-2930.52×2019-09-30
2021-11-3032.43×2019-09-30
2021-12-3134.16×2019-09-30
2022-01-3132.31×2019-09-30
2022-02-2860.07×2020-09-30
2022-03-3159.12×2020-09-30
2022-04-2959.01×2020-09-30
2022-05-3164.49×2020-09-30
2022-06-3061.47×2020-09-30
2022-07-2959.42×2020-09-30
2022-08-3163.12×2020-09-30
2022-09-3061.35×2020-09-30
2022-10-3178.03×2020-09-30
2022-11-3087.35×2020-09-30
2022-12-3085.38×2020-09-30
2023-01-3183.48×2020-09-30
2023-02-2822.18×2022-12-31
2023-03-3122.86×2022-12-31
2023-04-2822.65×2022-12-31
2023-05-3117.38×2023-03-31
2023-06-3017.41×2023-03-31
2023-07-3117.2×2023-03-31
2023-08-3117.54×2023-06-30
2023-09-2917.19×2023-06-30
2023-10-3118.02×2023-06-30
2023-11-3016.39×2023-09-30
2023-12-2917.33×2023-09-30
2024-01-3116.74×2023-09-30
2024-02-2915.97×2023-12-31
2024-03-2816.23×2023-12-31
2024-04-3014.44×2023-12-31
2024-05-31165.59×2024-03-31
2024-06-28176.77×2024-03-31
2024-07-31195.96×2024-03-31
2024-08-30203.54×2024-03-31
2024-09-30216.01×2024-03-31
2024-10-31228.84×2024-03-31
2024-11-29238.53×2024-03-31
2024-12-31237.99×2024-03-31
2025-01-31250.43×2024-03-31
2025-02-28294.51×2024-03-31
2025-03-31298.53×2024-12-31
2025-04-30283.85×2024-12-31
2025-05-30293.28×2024-12-31
2025-06-30295.38×2024-12-31
2025-07-31299.17×2024-12-31
2025-08-29300.98×2024-12-31
2025-09-30295.73×2024-12-31
2025-10-31319.15×2024-12-31
2025-11-2819.46×2025-09-30
2025-12-3118.98×2025-09-30
2026-01-3021.95×2025-09-30
2026-02-2721.91×2025-12-31
2026-03-3120.5×2025-12-31
2026-04-3019.25×2025-12-31
2026-05-2918.29×2026-03-31
2026-06-3017.19×2026-03-31
2026-07-3117.72×2026-03-31
2026-08-31—2026-06-30
2026-09-25—2026-06-30
Mean 55.76×Median 32.19×

ROIC

% · Annual / TTM

—
Gilead Sciences ROIC. Reported fiscal history.
Fiscal period% · Annual / TTM
FY 2009 Q2—
FY 2009 Q3—
FY 2009 Q4—
FY 2010 Q1—
FY 2010 Q2—
FY 2010 Q3—
FY 2010 Q4—
FY 2011 Q1—
FY 2011 Q2—
FY 2011 Q3—
FY 2011 Q4—
FY 2012 Q1—
FY 2012 Q2—
FY 2012 Q3—
FY 2012 Q427.79%
FY 2013 Q119.53%
FY 2013 Q219.75%
FY 2013 Q320.09%
FY 2013 Q420.39%
FY 2014 Q128.55%
FY 2014 Q245.86%
FY 2014 Q357.79%
FY 2014 Q471.91%
FY 2015 Q179.84%
FY 2015 Q279.49%
FY 2015 Q379.76%
FY 2015 Q479.56%
FY 2016 Q171.42%
FY 2016 Q263.19%
FY 2016 Q351.15%
FY 2016 Q442.21%
FY 2017 Q138.64%
FY 2017 Q234.8%
FY 2017 Q330.91%
FY 2017 Q411.55%
FY 2018 Q19.24%
FY 2018 Q26.07%
FY 2018 Q34.32%
FY 2018 Q414.84%
FY 2019 Q116.29%
FY 2019 Q215.81%
FY 2019 Q3—
FY 2019 Q4—
FY 2020 Q1—
FY 2020 Q2—
FY 2020 Q3—
FY 2020 Q40.55%
FY 2021 Q1—
FY 2021 Q2—
FY 2021 Q3—
FY 2021 Q417.27%
FY 2022 Q1—
FY 2022 Q2—
FY 2022 Q3—
FY 2022 Q413.8%
FY 2023 Q1—
FY 2023 Q2—
FY 2023 Q3—
FY 2023 Q4—
FY 2024 Q1—
FY 2024 Q2—
FY 2024 Q3—
FY 2024 Q4—
FY 2025 Q1—
FY 2025 Q2—
FY 2025 Q3—
FY 2025 Q4—
FY 2026 Q1—
FY 2026 Q2—

Capital allocation

% of tracked cash uses

$12,750M
Gilead Sciences capital allocation. Quarterly values. Missing values are unavailable.
PeriodCapexAcquisitionsBuybacksDividendsDebt repaymentsTracked uses
FY 2009 Q28.06% · $20.874MUnavailable91.94% · $238.179MUnavailableUnavailable100% · $259.053M
FY 2009 Q35.92% · $18.125M0% · $0M94.08% · $288.247MUnavailable0.01% · $0.023M100% · $306.395M
FY 2009 Q410.03% · $26.987M0% · $0M89.95% · $242.004MUnavailable0.02% · $0.049M100% · $269.04M
FY 2010 Q16.7% · $11.666MUnavailable93.3% · $162.52MUnavailableUnavailable100% · $174.186M
FY 2010 Q20.94% · $16.051MUnavailable99.06% · $1,691.561MUnavailableUnavailable100% · $1,707.612M
FY 2010 Q30.69% · $10.806MUnavailable99.31% · $1,552.974MUnavailableUnavailable100% · $1,563.78M
FY 2010 Q43.66% · $23.361M0% · $0M96.34% · $615.538MUnavailable0% · $0M100% · $638.899M
FY 2011 Q11.9% · $14.87M28.18% · $221.105M69.93% · $548.699MUnavailableUnavailable100% · $784.674M
FY 2011 Q22.38% · $26.635M32.86% · $367.503M64.76% · $724.163MUnavailableUnavailable100% · $1,118.301M
FY 2011 Q36.78% · $64.289M0% · $0M93.22% · $883.968MUnavailable0% · $0M100% · $948.257M
FY 2011 Q410.34% · $26.11M0% · $0M89.66% · $226.302MUnavailableUnavailable100% · $252.412M
FY 2012 Q10.21% · $23.199M96.47% · $10,751.636M0.19% · $20.77MUnavailable3.14% · $350M100% · $11,145.605M
FY 2012 Q25.95% · $37.392M0% · $0M38.35% · $241.021MUnavailable55.7% · $350M100% · $628.413M
FY 2012 Q310.71% · $66.584M0% · $0M33% · $205.209MUnavailable56.29% · $350M100% · $621.793M
FY 2012 Q421.47% · $269.871MUnavailable15.91% · $200.041MUnavailable62.62% · $787.139M100% · $1,257.051M
FY 2013 Q14.58% · $38.854M44.67% · $378.645M9.7% · $82.239MUnavailable41.04% · $347.896M100% · $847.634M
FY 2013 Q22.47% · $45.276M0% · $0M0% · $0MUnavailable97.53% · $1,787.641M100% · $1,832.917M
FY 2013 Q316.42% · $37.18M0% · $0M44.18% · $100.02MUnavailable39.4% · $89.187M100% · $226.387M
FY 2013 Q42.59% · $69.472M0% · $0M14.9% · $400.099MUnavailable82.51% · $2,215.167M100% · $2,684.738M
FY 2014 Q126.65% · $163.49M0% · $0M73.35% · $450.087MUnavailableUnavailable100% · $613.577M
FY 2014 Q27.05% · $90.997M0% · $0M92.95% · $1,200MUnavailableUnavailable100% · $1,290.997M
FY 2014 Q35.99% · $135.062M0% · $0M75.35% · $1,700M0% · $0M18.66% · $421M100% · $2,256.062M
FY 2014 Q44.1% · $167.451M0% · $0M48.95% · $2,000.523M0% · $0M46.95% · $1,919M100% · $4,086.974M
FY 2015 Q13.73% · $124MUnavailable90.28% · $3,001M0% · $0M5.99% · $199M100% · $3,324M
FY 2015 Q27.94% · $171MUnavailable41.76% · $900M29.37% · $633M20.93% · $451M100% · $2,155M
FY 2015 Q37.02% · $286MUnavailable74.83% · $3,050M15.38% · $627M2.77% · $113M100% · $4,076M
FY 2015 Q44.08% · $166MUnavailable75.06% · $3,051M15.1% · $614M5.76% · $234M100% · $4,065M
FY 2016 Q11.99% · $177MUnavailable89.99% · $8,000M6.6% · $587M1.42% · $126M100% · $8,890M
FY 2016 Q26.91% · $204MUnavailable33.92% · $1,001M21.21% · $626M37.95% · $1,120M100% · $2,951M
FY 2016 Q310.84% · $198MUnavailable54.76% · $1,000M34.12% · $623M0.27% · $5M100% · $1,826M
FY 2016 Q46.71% · $169MUnavailable39.71% · $1,000M24.58% · $619M28.99% · $730M100% · $2,518M
FY 2017 Q18.43% · $118MUnavailable40.36% · $565M49.07% · $687M2.14% · $30M100% · $1,400M
FY 2017 Q212.77% · $123MUnavailable13.5% · $130M70.61% · $680M3.12% · $30M100% · $963M
FY 2017 Q312.98% · $129MUnavailable15.39% · $153M68.61% · $682M3.02% · $30M100% · $994M
FY 2017 Q4UnavailableUnavailable4.22% · $106M27.18% · $682M68.59% · $1,721M100% · $2,509M
FY 2018 Q13.26% · $212MUnavailable15.97% · $1,039M11.58% · $753M69.19% · $4,500M100% · $6,504M
FY 2018 Q219.97% · $297MUnavailable30.26% · $450M49.76% · $740M0% · $0M100% · $1,487M
FY 2018 Q35.37% · $167MUnavailable14.45% · $449M23.87% · $742M56.31% · $1,750M100% · $3,108M
FY 2018 Q412.74% · $248MUnavailable49.43% · $962M37.82% · $736M0% · $0M100% · $1,946M
FY 2019 Q18.98% · $237MUnavailable31.61% · $834M30.97% · $817M28.43% · $750M100% · $2,638M
FY 2019 Q28.92% · $185MUnavailable28.36% · $588M38.59% · $800M24.12% · $500M100% · $2,073M
FY 2019 Q37.34% · $200MUnavailable8.14% · $222M29.49% · $804M55.03% · $1,500M100% · $2,726M
FY 2019 Q418.3% · $203MUnavailable9.47% · $105M72.23% · $801M0% · $0M100% · $1,109M
FY 2020 Q15.82% · $171M2.15% · $63M45.23% · $1,328M29.77% · $874M17.03% · $500M100% · $2,936M
FY 2020 Q22.47% · $143M81.83% · $4,741M0.93% · $54M14.77% · $856M0% · $0M100% · $5,794M
FY 2020 Q33.68% · $155M23.71% · $1,000M4.77% · $201M20.42% · $861M47.43% · $2,000M100% · $4,217M
FY 2020 Q40.86% · $181M95.05% · $19,938M0% · $0M4.09% · $858M0% · $0M100% · $20,977M
FY 2021 Q14.24% · $165M32.21% · $1,255M7.93% · $309M23.54% · $917M32.08% · $1,250M100% · $3,896M
FY 2021 Q210.37% · $119M8.01% · $92M3.75% · $43M77.87% · $894M0% · $0M100% · $1,148M
FY 2021 Q33.72% · $139M1.44% · $54M3.88% · $145M24.08% · $900M66.88% · $2,500M100% · $3,738M
FY 2021 Q47.43% · $156M0.05% · $1M2.33% · $49M42.57% · $894M47.62% · $1,000M100% · $2,100M
FY 2022 Q111.91% · $247M1.45% · $30M16.97% · $352M45.56% · $945M24.11% · $500M100% · $2,074M
FY 2022 Q26.4% · $143M49.24% · $1,101M3.22% · $72M41.14% · $920M0% · $0M100% · $2,236M
FY 2022 Q35.78% · $157M16.51% · $448M6.63% · $180M34.23% · $929M36.85% · $1,000M100% · $2,714M
FY 2022 Q48.59% · $181M10.35% · $218M37.61% · $792M43.45% · $915M0% · $0M100% · $2,106M
FY 2023 Q15.37% · $109M27.16% · $551M19.71% · $400M47.76% · $969M0% · $0M100% · $2,029M
FY 2023 Q29.42% · $139M16.46% · $243M10.16% · $150M63.96% · $944M0% · $0M100% · $1,476M
FY 2023 Q33.29% · $122M2.13% · $79M8.1% · $300M25.73% · $953M60.75% · $2,250M100% · $3,704M
FY 2023 Q413.55% · $215M17.58% · $279M9.45% · $150M59.42% · $943M0% · $0M100% · $1,587M
FY 2024 Q11.9% · $105M73% · $4,043M7.22% · $400M17.88% · $990M0% · $0M100% · $5,538M
FY 2024 Q24.06% · $130M4.74% · $152M3.12% · $100M30.33% · $972M57.75% · $1,851M100% · $3,205M
FY 2024 Q36.7% · $141M27.07% · $570M14.25% · $300M46.68% · $983M5.32% · $112M100% · $2,106M
FY 2024 Q49.47% · $147M4.83% · $75M22.55% · $350M62.69% · $973M0.45% · $7M100% · $1,552M
FY 2025 Q12.68% · $104M7.04% · $273M18.82% · $730M26.04% · $1,010M45.42% · $1,762M100% · $3,879M
FY 2025 Q26.45% · $107M1.27% · $21M31.79% · $527M59.95% · $994M0.54% · $9M100% · $1,658M
FY 2025 Q38.34% · $147M9.47% · $167M24.67% · $435M57.01% · $1,005M0.51% · $9M100% · $1,763M
FY 2025 Q410.02% · $205M29.77% · $609M11.24% · $230M48.58% · $994M0.39% · $8M100% · $2,046M
FY 2026 Q12.63% · $117M2.45% · $109M9.41% · $419M23.37% · $1,040M62.14% · $2,766M100% · $4,451M
FY 2026 Q21.1% · $140M87.91% · $11,209M2.78% · $355M8.07% · $1,029M0.13% · $17M100% · $12,750M

Tracked cash uses · SBC excluded

Sources and calculations

Company filings · USD · Last checked 2026-10-18. Missing inputs remain unavailable. Your chart selection and layout are saved in this browser for Gilead Sciences.

All charts share the selected dates. Quarterly/Yearly changes fiscal charts; valuation keeps completed daily closes on a published TTM basis. Later restatements can delay that basis. Historical mean, median and pricing labels use the selected range and do not estimate intrinsic fair value.

SBC deduction is an optional economic-cost scenario for FCF-based metrics. Missing SBC never becomes zero.

Revenue
Reported revenue from company filings.
Free cash flow
Operating cash flow − reported cash capital investment. PPE purchases are preferred; the productive-assets fallback also includes software and intangibles. Reflects the SBC option and can differ from issuer-defined FCF.
Net margin
Reported net income / revenue × 100.
P/E
Completed closing price × diluted shares / TTM earnings attributable to common shareholders.
ROIC
NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
Capital allocation
Reported cash uses as a percentage of tracked uses. Missing categories remain unavailable; SBC is noncash and excluded.
Reported revenue and sources